Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Non-Current Assets (2020 - 2026)

Rani Therapeutics Holdings' Non-Current Assets history spans 7 years, with the latest figure at $4.8 million for Q1 2026.

  • On a quarterly basis, Non-Current Assets fell 24.5% to $4.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $21.1 million, a 41.55% decrease, with the full-year FY2025 number at $5.3 million, down 23.08% from a year prior.
  • Non-Current Assets came in at $4.8 million for Q1 2026, down from $5.3 million in the prior quarter.
  • The five-year high for Non-Current Assets was $12.1 million in Q1 2024, with the low at $4.8 million in Q1 2026.
  • Historically, Non-Current Assets has averaged $7.4 million across 5 years, with a median of $7.1 million in 2023.
  • Biggest five-year swings in Non-Current Assets: soared 63.91% in 2024 and later plummeted 53.59% in 2025.
  • Year by year, Non-Current Assets stood at $7.1 million in 2022, then fell by 0.48% to $7.1 million in 2023, then decreased by 2.53% to $6.9 million in 2024, then decreased by 23.08% to $5.3 million in 2025, then dropped by 9.66% to $4.8 million in 2026.
  • Business Quant data shows Non-Current Assets for RANI at $4.8 million in Q1 2026, $5.3 million in Q4 2025, and $5.2 million in Q3 2025.